GBV 006
Alternative Names: GBV-006Latest Information Update: 28 May 2024
At a glance
- Originator Stanford University School of Medicine
- Developer Globavir Biosciences
- Class Antivirals
- Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
- No development reported Dengue; Hantavirus infections; Lassa fever; Marburg virus disease
- Discontinued Ebola virus infections; Respiratory syncytial virus infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Hantavirus-infections in USA
- 28 May 2024 No recent reports of development identified for preclinical development in Lassa-fever in USA
- 28 May 2024 No recent reports of development identified for preclinical development in Marburg virus disease in USA